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Molecular mechanisms of 
FSH muscular dystrophy 
pathogenesis	


















Facio:        refers to face	

Scapulo:    refers to shoulders	

Humeral:  refers to humerus (upper arm bone)	

Winging on both sides in a patient with 	







Great genetic and clinical heterogeneity	

Each patient may differ in severity	

Most patients exhibit symptoms by age 20	











Human chromosome 4q35, Normal D4Z4 n=11-150	







The FSHD1 genetic lesion is a deletion 	










A pathogenic FSHD1 deletion is complex	

Ø  The deletion itself is not pathogenic	

Ø  The 4qA sub-telomere is permissive, not pathogenic	

Ø  The 4qB sub-telomere is not permissive	

Ø  Requires at least 1 D4Z4 repeat unit for FSHD	

































A putatively pathogenic FSHD1 deletion 	























The deletion itself is not pathogenic	

The 4qA sub-telomere is permissive, not pathogenic	










FSHD2 is independent of the contraction	

Ø  The 4qA sub-telomere is required for FSHD1 and 2	





























4q	  ter	  FSHD1	  
4qA	  
FSHD2	   4q	  ter	  
4qA	  
=	  Hypermethylated	  CpGs	  
	  	  	  	  more	  heterochroma;c	  
=	  Hypomethylated	  CpGs	  




FSHD is linked to D4Z4, the A type subtelomere	

 and the epigenetic status of the 4q35 D4Z4 repeat	

The 3 types of FSHD are linked 
by epigenetic dysregulation	

FSHD1:  Dominant deletions at 4q35 D4Z4 array	

	
    Apparently low penetrance	

	












--Modifier of metastable epialleles	

	




IFSHD:  Infantile form of FSHD1 or FSHD2, much more severe	

	




4q	  ter	  FSHD1	  
4qA	  
FSHD2	   4q	  ter	  
4qA	  
=	  Hypermethylated	  CpGs	  
	  	  	  	  more	  heterochroma;c	  
=	  Hypomethylated	  CpGs	  








FSHD is linked to the A type subtelomere and 	

the epigenetic status of the 4q35 D4Z4 repeat	

FSHD results from an 
epigenetic-mediated 




























The FSHD causal gene:	

1. Should be misexpressed in FSHD (Up or down)	

	
à mRNA, protein, cell type, developmental timing	

	








Both FRG1 and DUX4 produce phenotypes consistent with FSHD when	

     overexpressed in animal models	






Deltoid	  –	  Expect	  	  
less	  pathology	  


















Subjects	  screened	  for	  FSHD	  





Wellstone family cohorts of muscle biopsies 	










FSHD1 affected and genetically unaffected 1st degree relatives	






























































Myogenic cultures from FSHD and unaffected first-
degree relatives have similar patterns of gene expression 
during proliferation and myogenic differentiation	

PAS	  =	  polyadenyla;on	  site	  	  	  	  	  	  	  NP	  =	  non-­‐permissive	  
	  	  	  	  	  	  	  	  =	  transla;on	  stop	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	  =	  permissive	  *	  
*	  
PAS	  
Exon	  1	  	   E2	   E3(P)	  
AAAAAAA	   -­‐Stable	  poly	  A	  mRNA	  
-­‐DUX4	  protein	  produced	  
-­‐DUX4	  expression	  is	  exclusive	  
	  	  	  	  to	  FSHD	  
*	  Exon	  1	  	   E2	   E3(NP)	  
-­‐Unstable	  mRNA	  
-­‐DUX4	  protein	  not	  made	  
-­‐Nontoxic	  
Chr 4qB or Chr 10qA or 10qB à Normal	









Lemmers et al. (2010) Science 329:1650	

FSHD permissive 4qA subtelomeres encode a third exon containing 	







“A Unifying Model for FSHD” based on DUX4	

(NP)	  
PAS	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  polyadenyla;on	  site	  	  	  	  	  	  	  NP	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  transla;on	  stop	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	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  permissive	  *	  
*	  
PAS	  
Exon	  1	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   E3(P)	  
AAAAAAA	   -­‐Stable	  poly	  A	  mRNA	  
-­‐DUX4	  protein	  produced	  
-­‐DUX4	  expression	  is	  exclusive	  
	  	  	  	  to	  FSHD	  
*	  Exon	  1	  	   E2	   E3(NP)	  
-­‐Unstable	  mRNA	  
-­‐DUX4	  protein	  not	  made	  
-­‐Nontoxic	  
Chr 4qB or Chr 10qA or 10qB à Normal	









Lemmers et al. (2010) Science 329:1650	

FSHD permissive 4qA subtelomeres encode a third exon containing 	







“A Unifying Model for FSHD” based on DUX4	

(NP)	  
DUX4-FL expression leads to massive loss of 
developing myogenic cells	

Wuebbles et al. (2010) IJCEP	

1 pg DUX4-fl 	

    mRNA	









T. Jones et al. (2012) Hum. Mol. Genet 21:4419	





T. Jones et al. (2012) Hum. Mol. Genet 21:4419	

DUX4-fl mRNA expression is expressed in both	

FSHD1-derived and unaffected muscle biopsies	

T. Jones et al. (2012) Hum. Mol. Genet 21:4419	

Differentiated myogenic cells from genetically FSHD1	

and control subjects express DUX4-FL protein	











DUX4-FL expression in myogenic 	

cells from FSHD affected unaffected subjects 	

suggests a quantitative model of pathogenesis	

T. Jones et al. (2012) Hum. Mol. Genet 21:4419	

4q	  ter	  FSHD1	  
4qA	  
FSHD2	   4q	  ter	  
4qA	  
=	  Hypermethylated	  CpGs	  
	  	  	  	  more	  heterochroma;c	  
=	  Hypomethylated	  CpGs	  




FSHD is linked to the permissive 4qA subtelomere, 	
























The FSHD causal gene:	

1. Should be misexpressed in FSHD (Up or down)	

	
à mRNA, protein, cell type, developmental timing	

	








DUX4 fulfills these criteria	






Many DUX4-FL responsive genes are 
upregulated in FSHD myotubes 
(biomarkers)	

Oliver King, et al. (2012)	

Increased DUX4-fl expression 
appears necessary* but alone is 
not sufficient for FSHD	

FSHD-derived myoblasts are 
epigenetically poised to express DUX4-fl	











FSHD derived myogenic cells are epigenetically	













































































































FSHD subjects show individual variability in the	

stability of DUX4-fl epigenetic repression	

The 4q35 D4Z4 in FSHD exists as differentially 	

	


















Differentiated myogenic cells from genetically 	









15A = 66 yr old	





28A = 44 yr old	










































DUX4-FL expression in myogenic cells from 	

FSHD1 subjects that show no clinical manifestation	

of the disease suggests modifiers of disease	

T.	  Jones	  et	  al.	  (2012)	  
4q	  ter	  FSHD1	  
4qA	  
FSHD2	   4q	  ter	  
4qA	  
=	  Hypermethylated	  CpGs	  
	  	  	  	  more	  heterochroma;c	  
=	  Hypomethylated	  CpGs	  




DUX4 expression alone is not 	














































     DUX4-fl	

3.  Block or reduce	




































     DUX4-fl	

3.  Block or reduce	







Key to therapy may lie with identifying the disease modifiers	

Analysis of DUX4 mRNA and protein 
expression in muscles and myogenic cells 
from FSHD subjects and unaffected relatives	
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